Juskaran S. Chadha, DO
Dr. Juskaran S. Chadha is a medical oncologist and Assistant Professor at the University of South Florida, Morsani College of Medicine as well as at Moffitt Cancer Center in Tampa, Florida. His clinical focus is solid tumor oncology, with special interests in genitourinary tract tumors, including prostate cancer, bladder cancer, kidney cancer, testicular cancer, and thoracic malignancies like pleural mesothelioma. He is board-certified in medical oncology, hematology, and internal medicine.[1]
Education and Career
Dr. Chadha earned his osteopathic medical degree at the NYIT College of Osteopathic Medicine. He completed an internship and residency in Internal Medicine at Icahn School of Medicine at Mount Sinai and a fellowship in Hematology and Oncology at the Donald and Barbara Zucker School of Medicine at Hofstra Northwell Health Cancer Institute.[1]
Professional Memberships and Activities
Dr. Chadha is a member of several professional medical organizations, including the American Society of Clinical Oncology, the American College of Physicians, and the American Society of Hematology.
Research
Dr. Chadha’s research interests center on solid tumor oncology and precision medicine. He has more than 10 publications and over 50 citings. His most recent publications include:[1]
- Ionescu F, Nguyen J, Segura CM, Paravathaneni M, Grass GD, Johnstone P, Zacharias NM, Pettaway CA, Lu X, Kim Y, Whiting J, Dhillon J, Eschrich SA, Chadha J, Gullapalli K, Roman Souza G, Miyagi H, Manley BJ, Spiess PE, Chahoud J. Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage. Cancers (Basel). 2024 Jan.16(2). Pubmedid: 38275860. Pmcid: PMC10814242.
- Paravathaneni M, Safa H, Joshi V, Tamil MK, Adashek JJ, Ionescu F, Shah S, Chadha JS, Gilbert S, Manley B, Semaan A, Jim HSL, Kalos D, Kim Y, Spiess PE, Chahoud J. 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis. EClinicalMedicine. 2024 Feb.68:102413. Pubmedid: 38273886. Pmcid: PMC10809115.
- Chadha J, Chahoud J. Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339-348. Eur Urol Oncol. 2024 Feb.7(1):172. Pubmedid: 37357090.
- Turner K, Kim DW, Gonzalez BD, Gore LR, Gurd E, Milano J, Riccardi D, Byrne M, Al-Jumayli M, de Castria TB, Laber DA, Hoffe S, Costello J, Robinson E, Chadha JS, Rajasekhara S, Hume E, Hagen R, Nguyen OT, Nardella N, Parker N, Carson TL, Tabriz AA, Hodul P. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial. Contemp Clin Trials Commun. 2024 Apr.38:101271. Pubmedid: 38440777. Pmcid: PMC10910065.
- Mason NT, Joshi VB, Adashek JJ, Kim Y, Shah SS, Schneider AM, Chadha J, Jim HSL, Byrne MM, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023 Jun.6(3):331-338. Pubmedid: 36797084.
- Parza K, Mustasam A, Ionescu F, Paravathaneni M, Sandstrom R, Safa H, Grass GD, Johnstone PA, Eschrich SA, Chadha J, Zacharias N, Pettaway CA, Spiess PE, Chahoud J. The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma-A Systematic Review. Cancers (Basel). 2023 Jul.15(14). Pubmedid: 37509374. Pmcid: PMC10378259.
- David J, Chumbalkar V, Chadha J. An insight into metastatic Leydig cell tumors: A case report. SAGE Open Med Case Rep. 2023 Jul.11. Pubmedid: 37434893. Pmcid: PMC10331185.
- Cui J, Tabbara S, Chadha J. The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare EGFR R776H mutation with Osimertinib: Case report. SAGE Open Med Case Rep. 2023 Aug.11. Pubmedid: 37663150. Pmcid: PMC10469228.
